DermTech, Inc. (NASDAQ:DMTK)

Bad profit ratios

DMTK has already gained FDA approval for its Melanoma sticker diagnostic technology they also own ALL patents on its tech. They are also in the process of completing phase 3 trials for the same sticker technology for the other two most common skin cancers Basal Cell and squeamish cell carcinomas with FDA approval for these they have the trifecta on ALL skin cancers for non invasive testing with 99.9% accuracy. DMTK has also made in roads with insurance companies Medicare as well as Anthem. Cost: The standard for diagnosing skin cancers are expensiveness and invasive biopsies the average cost to insurance companies is $2000 for this. DMTK's patch technology is 99.9% accurate and it's cost to insurance companies is under $800 thus saving insurers huge sums of money.As well as patients the pain and scaring of unnecessary biopsies. I see insurance companies not only coming on board with DMTK but making it a requirement for doctors to use the patch first biopsy second meaning if a doctor does a biopsy when the patch could have been used the billing will be rejected by the insurer. These are but a few of the ways DMTK will change the market over the next ten years. My wife and I hold a large position in DMTK and for us we see this is a 10X profit stock by 2030.